Euclidean Capital
Overview
Euclidean Capital is a single-family office established to manage the personal wealth of the late James Simons, the founder of Renaissance Technologies. Based in New York City, the firm makes diversified investments in both public and private markets, with a focus on sectors such as biotechnology, life sciences, financial services, and artificial intelligence.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Circle Pharma | Sep 2026 | Series E | Co-investor |
| Savvy Wealth | Sep 2026 | Series C | Co-investor |
| Leal Therapeutics | Aug 2026 | Series A Extension | Co-investor |
| InduPro | Aug 2026 | Series B | Co-investor |
| Ripple Foods | Dec 2025 | Strategic | Co-investor |
For institutional investors. Book with your work email.
Key People
John Alberg
Founder & Managing Partner
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Euclidean Capital based?
Euclidean Capital is headquartered in New York City, New York, United States.
When was Euclidean Capital founded?
Euclidean Capital was founded in 2009.
How many portfolio companies does Euclidean Capital have?
Euclidean Capital has 38 portfolio companies in Caplight's dataset.
What are some companies in Euclidean Capital's portfolio?
Recent investments visible on Caplight include Circle Pharma, Savvy Wealth, Leal Therapeutics, InduPro, Ripple Foods.
What was Euclidean Capital's most recent investment?
Euclidean Capital's most recent investment on Caplight was in Circle Pharma in 2026.
What sectors does Euclidean Capital focus on?
Euclidean Capital focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, FinTech, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Consumer & Commerce, Frontier & Industrial Tech, FinTech, FinTech, Healthcare & Life Sciences, Frontier & Industrial Tech, FinTech, FinTech, Cybersecurity, FinTech, Healthcare & Life Sciences, Energy & Sustainability, Energy & Sustainability, Cybersecurity, AI, Data & Cloud Infrastructure, Enterprise Software, Enterprise Software, AI, Data & Cloud Infrastructure, Enterprise Software, FinTech, Frontier & Industrial Tech, AI, Data & Cloud Infrastructure, Enterprise Software, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech, Enterprise Software, Enterprise Software, Enterprise Software, Enterprise Software, Enterprise Software, Enterprise Software, Enterprise Software, Enterprise Software, Enterprise Software, Real Estate & PropTech, Frontier & Industrial Tech, Energy & Sustainability.
What company stages does Euclidean Capital focus on?
Euclidean Capital typically invests at the Mid stage.
What is Euclidean Capital's AUM?
Euclidean Capital's assets under management are estimated between $305.7M and $1.0B.